Orbit Discovery and Evergreen Theragnostics Expand Peptide Collaboration for Radiopharmaceuticals

• Orbit Discovery and Evergreen Theragnostics expand their partnership, initiated in April 2023, to accelerate peptide-based radiopharmaceutical innovation.

• The collaboration aims to optimise peptide ligands for precision cancer therapies using Orbit’s screening platform and Evergreen’s clinical expertise.

Orbit Discovery, a leader in peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical firm, have announced the extension of their partnership to develop novel targeting peptides. Building on their initial agreement from April 2023, the collaboration focuses on identifying high-affinity peptide ligands optimised for radiopharmaceutical delivery in oncology and other therapeutic applications.

Under this partnership, Orbit Discovery will utilise its proprietary screening platform to discover and optimise peptide candidates. Meanwhile, Evergreen Theragnostics brings its expertise in radiopharmaceutical development and clinical translation to the initiative. Together, the companies aim to streamline the path from discovery to clinical implementation, targeting next-generation radiopharmaceutical therapies.

“Our collaboration with Evergreen Theragnostics has proven to be a powerful example of how complementary expertise can drive ground-breaking innovation,” said Dr. Neil Butt, CEO of Orbit Discovery. “We are excited to continue building on our achievements and leveraging our proprietary platform to discover peptides with therapeutic potential.”

Dr. Thomas Reiner, CSO of Evergreen Theragnostics, added, “The Company’s peptide discovery platform has proven invaluable in our mission to develop precision-targeted radiopharmaceuticals. Together, we aim to expedite the journey from discovery to clinical application, creating novel therapies with the potential to improve outcomes for cancer patients.”